Le Lézard
Classified in: Health
Subjects: CCA, FVT

The Cigna Group's First Quarter 2024 Earnings Release Details


BLOOMFIELD, Conn., April 11, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its first quarter 2024 financial results on Thursday, May 2, 2024, and will host a conference call the same day.

First quarter 2024 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows:

Live Call
(888) 566-1889 (Domestic)
(773) 799-3989 (International)
Passcode: 05022024

Replay
(866) 407-9272 (Domestic)
(203) 369-0617 (International)

It is strongly suggested that participants dial in to the conference call by 8:15 a.m. ET on May 2. A replay of the call will be available from 12:30 p.m. ET on May 2 until 11:59 p.m. ET on May 16, 2024. Additionally, the conference call will be available on a live internet webcast at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Investor Relations section of The Cigna Group's website. Please note that this feature will be in listen-only mode.

A copy of the company's news release and financial supplement will be available on The Cigna Group's website in the Investor Relations section at https://investors.thecignagroup.com/overview/default.aspx, no later than 6:30 a.m. ET on May 2.

About The Cigna Group

The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 183 million customer relationships around the world. Learn more at thecignagroup.com.

Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
[email protected]

Media Contact
Justine Sessions
1 (860) 810-6523
[email protected]

SOURCE The Cigna Group


These press releases may also interest you

at 02:05
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and...

at 01:18
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
. Hansa Biopharma, "Hansa" (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American...

at 01:05
FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with...

at 01:05
Innate Pharma: Clarification Regarding SAR443579 Designation
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by...

at 00:01
ZYMFENTRAtm (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis
Celltrion USA announced today...

at 00:01
New Peer-Reviewed Clinical Studies Show SonarMD Reduces Emergency Department Visits and Hospitalizations for Patients with Ulcerative Colitis and Crohn's Disease
SonarMD today presented positive results from two large, longitudinal studies evaluating several major drivers of medical costs in people living with Inflammatory Bowel Disease (IBD) ? defined as people living with ulcerative colitis or Crohn's...

More news about Health...


News published on and distributed by: